

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF **WILLIAM N. WASHBURN ET AL.**FOR: **SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR**APPLICATION NO: **10/763,878**APPLICATION DATE: **01/23/2004**PATENT NO: **7,342,127**PATENT GRANT DATE: **11/MAR/2008**ART UNIT: **1621**EXAMINER: **PUTTLITZ, KARL J.**CONFIRMATION NO: **6011**USPTO CUSTOMER NO: **23914****TRANSMITTED VIA EFS-WEB**

Certificate of Corrections Branch

Commissioner for Patents

PO BOX 1450

Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT
FOR USPTO MISTAKE (37 C.F.R. §1.322)



Sir:

The patentees through their attorney hereby respectfully request that a certificate of correction be issued to correct printing errors in accordance with the attached Certificate of Correction Form 1050.

Pursuant to 37 C.F.R. §1.322, patentees request that a certificate of correction enclosed herewith be issued for mistakes by the Patent and Trademark Office. Support for the requested corrections are tabulated in Table 1.

Table: Mistakes made by the USPTO

Corrections requested in the patent:	Errors shown correctly in Amendment filed May 29, 2007:
Col. 55, line 8, after "alkyl", insert -- ; --.	Page 2, line 16.
Col. 57, lines 3 to 9, after first structure, insert -- or --.	Page 4, lines 28-32.


Corrections requested in the patent:	Errors shown correctly in Amendment filed May 29, 2007:
<p>Col. 57, lines 26 to 31, change</p> <p>“</p>  <p>”</p> <p>to</p> 	<p>Page 5, lines 3-6.</p>

Please send the certificate to the address registered with customer number 23914. The assignments on the above patent were recorded on May 17, 2004, and can be found on Reel 014636, Frame 0054 (6 pages), recorded on May 17, 2004, and can be found on Reel 014636, Frame 0068 (6 pages), and recorded on June 10, 2004, and can be found on Reel 014716, Frame 0055 (7 pages), to Assignee, Bristol-Myers Squibb Company, respectively.

In that the errors listed above are ascribable to the USPTO, no fee is believed to be due. In any fee not accounted for is due in connection herewith, the Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
Phone: 609-252-3453
Date: 6/10/08


Maureen S. Gibbons
Attorney for Applicants
Reg. No. 44,121